Sangamo Biosciences Inc. (SGMO)
-NasdaqGS 12.00 
1.51(14.39%) Oct 1, 4:00PM EDT|After Hours
:
12.02 0.02 (0.17%) Oct 1, 7:59PM EDT
| Prev Close: | 10.49 |
|---|
| Open: | 10.47 |
|---|
| Bid: | 12.02 x 900 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 15.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 21-Oct-13 |
|---|
| Day's Range: | 10.45 - 12.01 |
|---|
| 52wk Range: | 4.92 - 12.01 |
|---|
| Volume: | 2,123,630 |
|---|
| Avg Vol (3m): | 733,208 |
|---|
| Market Cap: | 649.27M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Tue, Oct 1)
- Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment OptionPR Newswire(Mon, Sep 23)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, Sep 21)
- Sangamo: A Fiery Biotech With A Product Poised To Go Down In Flames?at Seeking Alpha(Fri, Sep 20)
- Grab SGMO Even Lower Than Its Secondary?at Forbes(Fri, Sep 20)
- Sangamo Prices SharesZacks(Thu, Sep 19)
- 4 Biotech Stocks Triggering Breakout Tradesat TheStreet(Thu, Sep 19)
- SANGAMO BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhiEDGAR Online(Wed, Sep 18)
- Sangamo BioSciences Announces Pricing Of Public Offering Of Common StockPR Newswire(Wed, Sep 18)
- SANGAMO BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Sep 17)
- Sangamo BioSciences Proposes Public Offering Of Common StockPR Newswire(Tue, Sep 17)
- SEC Charges 23 Funds With Short-Selling Violations on Stock Offeringsat TheStreet(Tue, Sep 17)
- Grading the Twitterverse's 2013 Biotech Stock Picksat TheStreet(Mon, Sep 16)
- Sangamo BioSciences announces presentation of clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects treated with SB-728-TPR Newswire(Thu, Sep 12)
- Why Sangamo Was Smart To Buy Ceregeneat TheStreet(Thu, Sep 12)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 22.35 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.43 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States.
View More